Trial Profile
A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2020
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Paclitaxel (Primary) ; Paclitaxel (Primary) ; Rivoceranib (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 31 Oct 2018 New trial record
- 25 Oct 2018 Status changed from not yet recruiting to recruiting.